TBPH News and Press, Theravance Biopharma Inc. From 04/12/24

2024-04-12 10:00:50 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Drug...

2024-04-12 08:00:07 ET Julian Harrison from BTIG issued a price target of $21.00 for TBPH on 2024-04-12 06:36:00. The adjusted price target was set to $21.00. At the time of the announcement, TBPH was trading at $8.93. The overall price target consensus is at $14.00 with...

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 PR Newswire DUBLIN , ...

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire Q4 2023 YUPELRI ® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million ...

SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...

2024-02-25 17:35:04 ET Major earnings expected after the bell on Monday include: Zoom Video Communications ( ZM ) Unity Software ( U ) ONEOK ( OKE ) Innovative Industrial Properties ( IIPR ) Workday ( WDAY ) Read the full article on Seeking ...

2024-02-23 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 PR Newswire DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial result...

2024-02-13 20:45:43 ET Summary Baupost Group's 13F portfolio value decreased from $5.21B to $4.59B this quarter. The portfolio is heavily concentrated with Liberty Global, Liberty SiriusXM, Viasat, Alphabet, and Fidelity National Information Services accounting for ~62% of the hol...

2024-01-16 08:19:18 ET Orbicular Pharmaceutical Technologies has agreed to resolve its patent fight with Theravance Biopharma ( NASDAQ: TBPH ) and Viatris ( NASDAQ: VTRS ) unit, Mylan, over the respiratory disorder therapy Yupelri. Per the terms of the agreement, Orbicul...